Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | GAA | P10253 | 2/20 | 0.72 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30684627 | 0.98 | KMT2A (0.70) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL27913634 | 0.87 | GPBAR1 (0.60) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL457706 | 0.86 | GPBAR1 (0.59) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL2475844 | 0.86 | GPBAR1 (0.59) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL4721779 | 0.84 | ALDH1A1 (0.56) | KMT2AMEN1GAAGPBAR1TSHR | |
| Hydrochloric Acid SCHEMBL3981907 | 0.84 | GPBAR1 (0.57) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL3068021 | 0.84 | GPBAR1 (0.61) | KMT2AMEN1GAAGPBAR1TSHR | |
| SCHEMBL903110 | 0.84 | KMT2A (1.00) | KMT2AMEN1GAATSHRHSD17B10 | |
| SCHEMBL19035 | 0.84 | KMT2A (0.67) | KMT2AMEN1GAAGPBAR1TSHR | |
| Hydrochloric Acid SCHEMBL30684542 | 0.83 | KMT2A (0.97) | KMT2AMEN1GAATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279908-A | Heteroaryl compounds for the treatment of cognitive disorders | 加的夫大学学院咨询有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | KMT2A 3283/4885MEN1 3740/4885GAA 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.